Triclabendazole Effect on Protease Enzyme Activity in the Excretory- Secretory Products of Fasciola hepatica in Vitro.

  • Yosef Shrifi Department of Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Ali Farahnak Department of Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Abolfazle Golestani Department of Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Mohamad Reza Eshraghian Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Ashkan Faridi Department of Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Mohamad Bagher Molaei Rad Department of Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Keywords: Excretory-Secretory product, F. hepatica, Protease, Triclabendazole

Abstract

 Background: Fasciola hepatica is one of the most important helminthes parasites and triclabendazole (TCBZ) is routinely used for treatment of infected people and animals. Secreted protease enzymes by the F. hepatica plays a critical role in the inva-sion, migration, nutrition and the survival of parasite and are key targets for novel drugs and vaccines. The aim of study was to determine the protease activity of ex-cretory- secretory products (ESP) of F. hepatica in the presence of TCBZ anthel-mintic. Methods: F. hepatica helminthes were collected and cultured within RPMI 1640 [TCBZ treated (test) and untreated (control)] for 6 h at 37 °C. ESP of treated and control were collected, centrifuged and supernatants were stored at -20°C. Protein concentrations were measured according to Bradford method. Protease enzymes activities of ESP samples were estimated by using sigma's non-specific protease activity assay. ESP protein bands were detected by sodium dodecyl sulfate poly-acrylamide gel electrophoresis (SDS-PAGE). Results: Mean protein concentrations in control and treated of ESP samples were determined 196.1 ±14.52 and 376.4 ±28.20 μg/ml, respectively. Mean protease enzymes activities in control and treated were 0.37 ±0.1 and 0.089 ±0.03 U/ml, respectively. Significant difference between proteins concentrations and protease enzymes activities of two groups was observed (P<0.05). SDS-PAGE showed dif-ferent patterns of protein bands between treated and control samples. Conclusion: The TCBZ reduced secreted protease enzymes activities and possibly effects on invasion, migration, nutrition and particularly survival of the parasite in the host tissues.

References

Spithill T, Smooker P, Copeman D. Fasciola gigantica: epidemiology, control, immunology and molecular biology. Oxon, Wallingford, UK; 1999. p. 465-525.

Mas-Coma, Human fascioliasis. in: J.A. Cotruvo, A. Dufour, G. Rees, J. Bartram, R. Carr, D.O. Cliver, G.F. Craun, R. Fayer, V.P.J. Gannon (Eds.), Waterborne Zoonoses: Identification, Causes and Control. IWA Publishing, London, 2004, pp. 305-322.

Acosta-Ferreira W, Vercelli-Retta J, Falconi LM. Fasciola hepatica human infection. Virchows Archiv A. 1979;383(3):319-27.

Mas‐Coma S, Valero MA, Bargues MD. Fasciola, Lymnaeids and Human Fascio-liasis, with a Global Overview on Disease Transmission, Epidemiology, Evolutio-nary Genetics, Molecular Epidemiology and Control. Adv Parasit. 2009;69:41-146.

Robinson MW, Dalton JP. Zoonotic helminth infections with particular emphasis on fasciolosis and other trematodiases. Philos T Roy Soc B . 200-9;364(1530):2763-76.

Andrews SJ (1999). The life-cycle of Fasciola hepatica. In: Dalton JP, ed. Fasciolosis CABI: Oxford, United Kingdom. pp 1–29.

Irving JA, Spithill TW, Pike RN, Whisstock JC, Smooker PM. The evolution of enzyme specificity in Fasciola spp. J Mol Evol. 2003;57(1):1-15.

Robinson MW, Tort JF, Lowther J, Donnelly SM, Wong E, Xu W, et al. Proteomics and Phylogenetic Analysis of the Cathepsin L Protease Family of the Helminth Pathogen Fasciola hepatica Expansion of a Repertoire of Virulence-associated Factors. Mol Cell Proteomics. 2008;7(6):1111-23.

Collins PR, Stack CM, O'Neill SM, Doyle S, Ryan T, Brennan GP, et al. Cathepsin L1, the Major Protease Involved in Liver Fluke (Fasciola hepatica) virulence propeptide cleavage sites and autoacti-vation of the zymogen secreted from gastrodermal cells. J Biol Chem . 2004;279(17):17038-46.

Chapman CB, Mitchell GF. Proteolytic cleavage of immunoglobulin by enzymes released by Fasciola hepatica.Vet Parasitol. 1982;11(2):165-78.

Smooker PM, Jayaraj R, Pike RN, Spithill TW. Cathepsin B proteases of flukes: the key to facilitating parasite control? Trends Parasitol. 2010;26(10):506-14.

Dixit AK, Dixit P, Sharma RL. Immunodiagnostic/protective role of cathepsin L cysteine proteinases secreted by Fasciola species. Vet Parasitol. 2008; 4:154(3-4):177-84.

Fairweather I. Triclabendazole: new skills to unravel an old (ish) enigma. J Helminthol. 2005;79(03):227-34.

Fairweather I, Boray JC. Mechanisms of fasciolicide action and drug resistance in Fasciola hepatica. Fasciolosis (ed JP Dalton). 1999:225-76.

Duthaler U, Smith TA, Keiser J. In vivo and in vitro sensitivity of Fasciola hepatica to triclabendazole combined with artesu-nate, artemether, or OZ78. Antim-icrob Agents Ch .2010;54(11):4596-604.

Farahnak, M. Anvar-Seyyedi, M. Jalali M. R. Esharghian .Study on glutathione s-transferase inhibition assay by triclaben-dazole on Fasciola spp. Acta Med Iran 2006. 44(6):371-376.

A Farahnak, A Golestani, MR Eshraghian . Activity of Superoxide Dismutase (SOD) Enzyme in the Excretory-Secreto-ry Products of Fasciola hepatica and F. gigan-tica Parasites. Iranian J Parasitol: 2013;8(1): pp. 167-170.

Maizels R. Parasite antigens, parasite genes: a laboratory manual for molecular parasitology: CUP Archive; 1991.

Cupp-Enyard C. Sigma's non-specific protease activity assay-casein as a subst-rate. Journal of visualized experiments: JoVE. 2008(19).

de Souza CP, Magalhaes KG, Passos LK, Pereira dos Santos GC, Ribeiro F, Katz N. Aspects of the maintenance of the life cycle of Fasciola hepatica in Lymnaea columella in Minas Gerais, Brazil. Mem Inst Oswaldo Cruz. 2002;97(3):407-10.

Stitt A, Fairweather I. Fasciola hepatica: disruption of the vitelline cells in vitro by the sulphoxide metabolite of triclabe-ndazole. Parasitol Res. 1996;82(4):333-9.

Tansatit T, Sahaphong S, Riengrojpitak S, Viyanant V, Sobhon P. Fasciola gigantica: the in vitro effects of artesunate as com-pared to triclabendazole on the 3-weeks-old juvenile. Exp Parasitol. 2012;131(1):8-19.

Stitt AW, Fairweather I, Mackender RO. The effect of triclabendazole ("Fasinex") on protein synthesis by the liver fluke, Fasciola hepatica. Int J Parasitol. 199-5;25(4):421-9.

Bennett JL, Kohler P. Fasciola hepatica: action in vitro of triclabendazole on immature and adult stages. Exp Parasitol. 1987;63(1):49-57.

Carmona C, Dowd AJ, Smith AM, Dalt-on JP. Cathepsin L proteinase secreted by Fasciola hepatica in vitro prevents antibody-mediated eosinophil attachment to newly excysted juveniles. Mol Biochem Parasitol . 1993;62(1):9-17.

Berasain P, Carmona C, Frangione B, Dalton JP, Goñi F. Fasciola hepatica:Parasite-Secreted Proteinases Degrade All Human IgG Subclasses: Determination of the Specific Cleavage Sites and Identification of the Immunoglobulin Fragments Produced. Exp parasitol. 2000;94(2):99-110.

Serradell MC, Guasconi L, Cervi L, Chiapello LS, Masih DT. Excretory-secretory products from Fasciola hepatica induce eosinophil apoptosis by a caspase-dependent mechanism. Vet Immunol Immunop . 2007;117(3):197-208.

How to Cite
1.
Shrifi Y, Farahnak A, Golestani A, Eshraghian MR, Faridi A, Molaei Rad MB. Triclabendazole Effect on Protease Enzyme Activity in the Excretory- Secretory Products of Fasciola hepatica in Vitro. IJPA. 9(1):107-13.
Section
Articles